Dementia Vaccine UK 2026: NHS Status, Trials and the Honest Picture

Britain has a tau-vaccine trial running in Edinburgh and a planned shingles-vaccine dementia study — but no NHS-approved dementia vaccine in 2026.

Let’s answer the headline question directly: as of May 2026, there is no dementia vaccine available on the NHS. That doesn’t mean nothing is happening. The UK research picture is busy. Scottish Brain Sciences in Edinburgh has become the first European site for a clinical trial of a tau-targeting vaccine. A major UK trial is being planned to see if the shingles vaccine might lower dementia risk. And while new antibody drugs have been approved by the UK regulator, they are not routinely funded for NHS use. This explainer will cut through the noise, clarify what’s actually happening in UK trials and the NHS, and outline the practical steps you can take right now.

Is there a dementia vaccine on the NHS in 2026?

The simple answer is no. The NHS does not offer any approved vaccine for preventing or treating dementia in 2026. It’s important to distinguish between a vaccine and the new drugs making headlines. Lecanemab (brand name Leqembi) was approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in November 2024 for early Alzheimer’s disease. However, the National Institute for Health and Care Excellence (NICE) has not recommended it for routine NHS funding, citing a modest benefit relative to its high cost and the complex infusion infrastructure required. Donanemab, from Eli Lilly, is following a similar path: MHRA-approved, but not routinely available on the NHS.

These are not vaccines; they are antibody drugs given by regular infusion. They are available privately, but at a significant cost, typically running into tens of thousands of pounds per year. The NHS standard offer for dementia remains diagnosis, post-diagnostic support, and symptomatic treatments.

The UK trials worth knowing about

While no vaccine is approved, several research efforts are underway in the UK. A notable development is at Scottish Brain Sciences in Edinburgh. It became the first clinical site in the UK and Europe to administer a dose in the Janssen ReTain study. This is an active immunotherapy trial testing a vaccine designed to target the tau protein, which forms harmful tangles in the brains of people with Alzheimer’s. Separately, researchers are designing a large UK trial to test whether the shingles vaccine can help prevent dementia. This planned study, using the University of Exeter’s PROTECT platform, follows intriguing observational data suggesting people who received the shingles vaccine were around 16% less likely to develop dementia. The trial aims to find out if this link is causal. Eight Phase 3 Alzheimer’s trials are scheduled to report results in 2026, including the important TRAILBLAZER-ALZ 3 trial, which is testing Eli Lilly’s donanemab in early-stage disease.

Vaccine vs monoclonal antibody — what is the actual difference?

The terms are often used loosely, but the science differs. A vaccine, or active immunotherapy, works by training your own immune system to produce antibodies against a specific target, like amyloid plaques or tau tangles. In principle, it could be given as a short course of injections. A monoclonal antibody drug, like lecanemab or donanemab, is a passive immunotherapy. It involves infusions of pre-made antibodies that do the job for you. The effect only lasts as long as you keep receiving the regular infusions. The vaccine route is more attractive long-term—it would be cheaper and far easier to deliver globally—but it has proven much harder to develop successfully. Most past dementia vaccine candidates have failed in later trial stages due to safety or efficacy issues.

What you can do now if you are worried about dementia

Feeling anxious about your own memory or a relative’s is completely understandable. The most important first step on the NHS is to book an appointment with your GP. Explain your concerns; they can initiate a memory assessment. This is the gateway to the NHS dementia pathway. Your GP may refer you to a memory clinic for a specialist assessment, which can include neuropsychological testing, blood tests, and brain imaging like an MRI or CT scan if needed.

Beyond the clinical pathway, there are evidence-based actions. The Lancet Commission’s 2024 update identifies 14 modifiable risk factors. You can work on these now: correct hearing loss with aids if needed, manage high blood pressure, control diabetes, treat depression, engage in regular physical activity, stay socially connected, stop smoking, moderate alcohol intake, reduce exposure to air pollution, prevent head injuries, and address obesity, vision loss, and high cholesterol.

You can also volunteer for research via the official NIHR portal, Join Dementia Research. Finally, if you are in the eligible age group for the shingles vaccine (currently 65 and 70+ on the NHS), take it. While a potential dementia benefit is an emerging research question, the standard reason—preventing the painful shingles rash—is itself a strong one.

Lecanemab, donanemab and the NHS — the honest picture

Both lecanemab and donanemab have been approved by the MHRA, the UK’s drug regulator. However, approval is not the same as routine NHS availability. NICE, which decides on cost-effectiveness for the NHS in England, has so far not recommended lecanemab for routine use. Their assessment weighed a modest clinical benefit against the high drug cost and the significant resource implications of setting up fortnightly infusion services across the NHS.

The debate is informed by independent analysis; a Cochrane review raised concerns that the anti-amyloid drugs on the market may not deliver clinically meaningful benefit for most patients. The UK Dementia Research Institute has responded to this ongoing discussion. The result is that you cannot get these drugs on the NHS outside of a clinical trial. Some patients do access them privately, but this involves substantial personal cost. The NICE evaluation for donanemab is still pending, but it is likely to face similar scrutiny.

Frequently Asked Questions

Is the dementia vaccine available on the NHS in 2026?

No. There is no approved or NHS-funded dementia vaccine in May 2026. Research is ongoing in clinical trials, but no vaccine has completed the necessary testing for regulatory approval and routine use.

Where is the UK dementia vaccine trial happening?

Scottish Brain Sciences in Edinburgh is the first UK and European site for the Janssen ReTain study, an active immunotherapy trial targeting the tau protein in Alzheimer’s disease. A separate large UK trial of the shingles vaccine is being designed by the University of Exeter.

Can the shingles vaccine actually prevent dementia?

It is not proven. Observational data suggested a 16% lower dementia rate in people who had the vaccine. A major UK trial is being designed to test if this is a causal relationship. For now, the proven reason to get the jab is to prevent shingles itself.

Can I get lecanemab on the NHS?

No, not routinely. NICE has not recommended it for NHS funding due to its cost and modest benefit. It is available privately at significant cost. You may also access it by participating in a clinical trial.

What can I do now to reduce my dementia risk?

Focus on the modifiable risk factors identified by the Lancet Commission: manage your hearing, blood pressure, and diabetes; stay physically and socially active; quit smoking; moderate alcohol; and address depression, obesity, and high cholesterol. See your GP if you have memory concerns.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.